Biotech Stocks' Research Reports Released on Paratek Pharma, MannKind, Array BioPharma, and INSYS Therapeutics
NEW YORK, Dec. 20, 2017 /PRNewswire/ -- In keeping with the commitment to dynamically provide members with timely information, WallStEquities.com has issued free tailored Stock Review on PRTK, MNKD, ARRY, and INSY which is a click away at www.wallstequities.com/registration. On Tuesday, the NASDAQ Composite ended the day at 6,963.85, down 0.44%; the Dow Jones Industrial Average edged 0.15% lower, to finish at 24,754.75; and the S&P 500 closed at 2,681.47, marginally slipping 0.32%. Losses were broad based as all sectors finished the trading session in red. WallStEquities.com has initiated research reports on the following Biotechnology stocks: Paratek Pharmaceuticals Inc. (NASDAQ: PRTK), MannKind Corp. (NASDAQ: MNKD), Array BioPharma Inc. (NASDAQ: ARRY), and INSYS Therapeutics Inc. (NASDAQ: INSY). Following registration on Wall St. Equities, get access to today's free stock reports at:
www.wallstequities.com/registration
Paratek Pharmaceuticals
Boston, Massachusetts headquartered Paratek Pharmaceuticals Inc.'s stock finished Tuesday's session 0.56% lower at $17.85 with a total trading volume of 431,030 shares, which was above its three months average volume of 356.62 thousand shares. The stock has gained 27.05% in the previous twelve months and 15.91% since the start of this year. The Company's shares are trading below their 50-day moving average by 14.47%. Moreover, shares of Paratek Pharma, which focuses on the development and commercialization of therapeutics based upon tetracycline chemistry in the US, have a Relative Strength Index (RSI) of 34.96. Start your free membership with our free report on PRTK at:
www.wallstequities.com/registration/?symbol=PRTK
MannKind
Shares in Westlake Village, California headquartered MannKind Corp. declined 7.25%, ending yesterday's session at $2.56 with a total trading volume of 2.62 million shares. The stock has gained 29.29% in the previous three months. The Company's shares are trading above their 200-day moving average by 24.28%. Moreover, shares of MannKind, which focuses on the discovery, development, and commercialization of therapeutic products for diabetes diseases in the US, have an RSI of 26.36. Gain free access to the research report on MNKD at:
www.wallstequities.com/registration/?symbol=MNKD
Array BioPharma
On Tuesday, Boulder, Colorado headquartered Array BioPharma Inc.'s stock saw a rise of 0.65%, to close the day at $10.87. A total volume of 3.97 million shares was traded, which was higher than their three months average volume of 3.01 million shares. The Company's shares have advanced 24.80% over the last twelve months and 23.66% on an YTD basis. The stock is trading above its 200-day moving average by 13.58%. Additionally, shares of Array BioPharma, which focuses on the discovery, development, and commercialization of small molecule drugs to treat patients with cancer in North America, Europe, and Asia/Pacific, have an RSI of 47.42. Register for your free report coverage on ARRY at:
www.wallstequities.com/registration/?symbol=ARRY
INSYS Therapeutics
Shares in Chandler, Arizona headquartered INSYS Therapeutics Inc. ended the day 4.48% higher at $6.99. A total volume of 1.53 million shares was traded, which was above their three months average volume of 793.47 thousand shares. The stock has gained 30.17% in the last one month. The Company's shares are trading above their 50-day moving average by 13.54%. Furthermore, shares of INSYS Therapeutics, which develops and commercializes supportive care products, have an RSI of 67.21. Get the free research report on INSY at:
www.wallstequities.com/registration/?symbol=INSY
--
Wall St. Equities:
Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
WSE has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email info@wallstequities.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
NO WARRANTY
WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
https://wallstequities.com/legal-disclaimer/
CONTACT
For any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Email: info@wallstequities.com
Phone number: +21-32-044-483
Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
View original content:http://www.prnewswire.com/news-releases/biotech-stocks-research-reports-released-on-paratek-pharma-mannkind-array-biopharma-and-insys-therapeutics-300573785.html
SOURCE Wall St. Equities
